doi: 10.3390/nu12082189 2 AbbateA.ToldoS.MarchettiC.KronJ.Van TassellB
Early nausea and bloating frequently discourage patients from continuing therapy
The triple agonism gives prescribers a mechanistic rationale for trying retatrutide in plateau cases, but this remains an area requiring individual clinical judgment
Methods Human tissue acquisition and IRB Normal, de-identified human fetal intestinal tissue was obtained from the University of Washington Laboratory of Developmental Biology and was conducted with approval from the University of Michigan Institutional Review Board (IRB
[6] Proposed mechanisms for cardiovascular benefits of incretin-based therapies include: Vascular effects : Improved endothelial function and reduced arterial stiffness Anti-inflammatory actions : Decreased systemic inflammation and oxidative stress Metabolic improvements : Enhanced insulin sensitivity and reduced hepatic glucose production Hemodynamic changes : Blood pressure reduction, though with modest increases in heart rate Renal protection : Reduced albuminuria and preservation of kidney function The cardiovascular benefits appear partially independent of weight loss itself, suggesting potential cardioprotective properties of incretin pathway activation
Treatments with DSIP and DSIP-CBBBP are shown to effectively increase melatonin levels, indicating a stress-mitigating potential, whereas CBBBP treatment alone does not significantly affect melatonin levels, pointing to its limited efficacy in this context
